An unpublished FDA letter now controls Echo IQ's heart-failure timetable

This is investment research, not personal financial advice.

Echo IQ (ASX:EIQ) fell 50.0% on Wednesday, from A$1.28 to A$0.64, after the US Food and Drug Administration found its EchoSolv HF heart-failure software not substantially equivalent under the 510(k) pathway. About 34.5 million shares changed hands, nearly sixteen times the recent daily norm. The close cut the ordinary-equity value from roughly A$948 million to A$474 million (TradingView 2026; Google News 2026).

The fall is broadly proportionate to the evidence now available. Heart failure supplied much of the platform's blue-sky economics, and the FDA has removed both the assumed timetable and the assumed route. Yet the post-fall price has not reduced EchoSolv HF to zero. After allowing for the July placement cash, a plain sum-of-parts model still needs roughly a 40% probability of regulatory and commercial recovery to reproduce A$0.64. That is the tension: half the equity value disappeared, but an unpublished FDA response letter still carries a large part of what remains.

Half the equity value left with one letter

Echo IQ disclosed the decision after Tuesday's close. The announcement said the FDA had issued a not-substantially-equivalent, or NSE, determination after reviewing the EchoSolv HF 510(k). Management said the agency supplied detailed feedback across "several key areas". It did not publish the FDA letter, identify those areas, name a disputed predicate device, or quantify the extra clinical work and time needed (Echo IQ 2026a).

That omission matters more than the word "NSE" alone. The company's stated alternatives range from a direct resubmission to a modified regulatory pathway or changes to the product's intended use and scope. Those are not versions of the same remedy. A direct response based on analysis already in hand could be measured in months. A fresh prospective study, a different endpoint or a De Novo route could add years, cash expense and execution risk.

Management also said the decision did not invalidate the underlying Mayo Clinic validation data. That may be correct. It does not establish that the data answer the regulatory question attached to the proposed indication, workflow and comparator. The FDA clears a device for a specific intended use, not a sensitivity statistic in isolation. Investors have been told the algorithm performed well. They have not been told why that evidence failed the submitted equivalence test.

Wednesday's A$474 million loss in ordinary-equity value therefore prices more than a delay. It prices a lower chance of approval, a later commercial start and some risk that EchoSolv HF reaches the market with a narrower label. The immediate reaction looks rational because all three changed at once.

What an NSE closes, and what it leaves open

A 510(k) is a claim of substantial equivalence to a legally marketed device. The comparison covers intended use and technological characteristics, with performance evidence used where differences raise new questions of safety or effectiveness. An NSE decision means the submitted record did not establish that claim. It does not, by itself, mean the software cannot work or can never reach the US market (FDA 2024).

For Echo IQ, three regulatory branches now deserve separate treatment.

First, the company could address deficiencies and submit another 510(k). This is the least damaging branch if the problems concern presentation, statistical analysis, software documentation or a remediable predicate comparison. Second, it could narrow the proposed indication or alter the product so the equivalence argument fits. That can preserve a route to market while reducing the addressable workflow and revenue per deployment. Third, the agency may require a different route or materially different clinical evidence. That branch changes both time and capital.

The market cannot assign those branches tightly without the letter. Nor can an outside analyst reconstruct the regulator's objection from management's two-page release. The key evidence gap is unusually crisp: what exact deficiency drove the NSE decision, and does curing it require new patients rather than new analysis?

A regulatory setback also changes bargaining power. Echo IQ had prepared launch channels before clearance. Its expanded Mayo Clinic arrangement permits distribution of EchoSolv HF after authorization, and its proposed Pro Medicus relationship could place EchoSolv products inside large US imaging networks. Every deferred month delays revenue through those channels while payroll, clinical work and integrations continue.

EchoSolv AS is cleared; commercial proof is not

The surviving platform is more than a slide deck. EchoSolv AS, designed to assist assessment of severe aortic stenosis from ordinary echocardiograms, received FDA 510(k) clearance in FY2025. Echo IQ deployed it at Beth Israel Deaconess Medical Center and Mount Sinai, built links with ScImage and SARC MedIQ, and recorded rising processing volumes. The June 2026 quarter processed more than 10,200 echocardiograms, up about 11% sequentially and more than 400% from the prior comparable period (Echo IQ 2026b).

The commercial funnel also grew. At June 2026, management described more than 70 engaged hospitals and health systems, including three enterprise proposals covering over 300 hospitals. Its VIEW and SHADOW programs let hospitals test historical cases or run the software beside existing workflows before committing to full use. That design tackles a sales bottleneck: clinical governance, cybersecurity and procurement can obstruct hospital software long after a regulator clears it.

But the accounts set a harder boundary around those operating claims. FY2026 revenue was A$92,000, down from A$101,000, and cash receipts from customers were nil. The annual report explicitly said the 300-hospital proposals were not binding orders or committed revenue at year end (Echo IQ 2026b). Processing growth is evidence of use, not evidence of pricing power.

The reimbursement route is unsettled too. Echo IQ's application for a Category III CPT code for EchoSolv AS was not approved in the September 2025 cycle. Customers may use a miscellaneous code, and proposed US hospital-payment rules could open an interim route for eligible software services. Neither has yet converted usage into reported revenue.

That distinction changes the floor value. EchoSolv AS supplies a cleared product, reference institutions and a commercial learning loop. It does not yet supply enough cash receipts to anchor a conventional software multiple. Any valuation of the AS franchise has to start with future conversion assumptions rather than annual recurring revenue.

The Mayo numbers and the missing regulatory question

The case for EchoSolv HF was built around an independent retrospective validation conducted through Mayo Clinic Platform. On 17,000 patient echocardiograms, the company reported 99.5% sensitivity for identifying patients with heart failure and 91.1% specificity for identifying those without it. The study met its primary endpoint, and Echo IQ filed its 510(k) in December 2025 (Echo IQ 2026b).

Those headline numbers fit a screening use, but they leave several analytical gaps. Sensitivity and specificity do not reveal positive predictive value without disease prevalence. They do not show performance by heart-failure subtype, imaging equipment, hospital workflow or demographic cohort. And a retrospective classifier can perform well while the submitted device, indication or comparator fails a regulatory equivalence argument.

The company said the detailed FDA feedback may require changes to study design or statistical methodology. It also said there was no indication that the fundamental clinical performance had been invalidated (Echo IQ 2026a). Both statements can be true. A model may identify cases accurately and still lack the evidence package needed for its proposed market claim.

The addressable burden is large. Nearly 6.7 million US adults have heart failure, and the condition appeared on 452,573 US death certificates in 2023 (CDC 2026). Large prevalence does not create revenue by itself. Echo IQ needs authorization, hospital adoption, workflow integration and a payment mechanism in sequence. The NSE decision broke the first link for HF, at least temporarily.

A useful peer warning comes from HeartSciences, another listed company applying algorithms to cardiac signals. Its FY2026 10-K devotes substantial space to authorization risk, clinical-evidence demands, reimbursement uncertainty and the possibility that technically functioning software fails to achieve commercial adoption (HeartSciences 2026). Echo IQ has a different product and a stronger balance sheet, but it faces the same sequence of gates.

Five years of spending before revenue

The table below stays in the company's reporting currency, Australian dollars. Revenue, NPAT, operating cash flow and cash are source-reported. The final two columns are author computations. Gearing is set at zero because the filed balance sheets contain no interest-bearing borrowings. The return measure is a cash ROIC proxy: operating cash flow divided by average operating invested capital, where operating invested capital equals assets less cash, term deposits and non-interest liabilities. It is intentionally harsh and becomes extreme as the operating-capital denominator shrinks. The latest FY2026 computed cash ROIC proxy is negative 280.3%.

Year to June	Revenue (A$m)	NPAT (A$m)	OCF (A$m)	Cash (A$m)	Computed cash ROIC proxy	Computed gearing
2022	0.251	(5.992)	(2.585)	2.407	(44.4%)	0.0%
2023	0.107	(7.856)	(4.940)	3.276	(101.7%)	0.0%
2024	0.045	(5.409)	(3.924)	2.117	(89.6%)	0.0%
2025	0.101	(13.263)	(6.509)	6.618	(140.4%)	0.0%
2026	0.092	(18.566)	(10.564)	8.712	(280.3%)	0.0%

Sources: Echo IQ annual reports for FY2022 through FY2026 (Echo IQ 2022; Echo IQ 2023; Echo IQ 2024; Echo IQ 2025; Echo IQ 2026b). FY2025 also held A$11.518 million in a term deposit outside the cash line.

This is not a compounding record yet. Revenue has stayed below A$0.3 million for five years. Operating cash use has risen fourfold from FY2022. FY2026 employee costs increased to A$6.1 million from A$3.2 million, consulting and professional fees rose to A$3.5 million, and marketing expense reached A$0.8 million. That cost base reflects a US launch organization built before HF authorization.

The statutory loss contains a second owner-cost signal: share-based payments were A$6.2 million in FY2026, almost unchanged from FY2025. Removing that non-cash expense makes the accounting loss look less severe, but owners still absorb it through dilution. At 28 August, the company listed 77.65 million options and 11.875 million performance rights, on top of ordinary shares.

The history also shows why the FDA event affects valuation far more than this year's earnings. There is no mature profit stream to trim. Most of the pre-event equity value represented expected future adoption, with HF as the largest unapproved module.

A$105 million turns survival into an execution problem

Echo IQ entered July with only A$8.7 million of balance-sheet cash. It then issued 75.862 million shares at A$1.45, raising about A$110 million before costs. The placement was struck at an 8.8% discount to the prior traded price and lifted quoted ordinary shares to 736.725 million. Subsequent option exercises took that count to 740.725 million by 21 August (Echo IQ 2026c; Echo IQ 2026e).

The FDA update put available cash at about A$105.4 million (Echo IQ 2026a). Against FY2026 operating cash use of A$10.564 million, plus A$0.053 million of plant expenditure, the simple owner-cash consumption was A$10.617 million. A normalized view strips out A$0.763 million of grants and A$0.560 million of interest, producing A$11.887 million of cash operating outflow before capital expenditure.

That historical rate implies 8.9 years of funding. It is not a sensible planning rate because Echo IQ raised the money to increase US commercial, implementation and development spending. At A$20 million of annual cash use, the starting balance covers 5.3 years; at A$30 million, 3.5 years. This is a much stronger position than most pre-scale medical-software companies, and it makes near-term insolvency a weak bear argument.

The balance sheet does not remove opportunity cost. Capital deployed into an HF study that the FDA did not ask for, or into a sales team waiting on authorization, can still destroy per-share value. The July placement changed the central question from "can Echo IQ fund the next step?" to "which next step earns the best regulatory and commercial evidence per dollar?"

There is also conditional capital from Pro Medicus. The parties executed a convertible-note and option agreement in August, following a June heads of agreement for an initial A$10 million note and another A$10 million contingent on HF clearance. Funding remains tied to conditions, including a definitive commercial distribution agreement, and the August release did not publish the note's economic terms (Echo IQ 2026d). Until those conditions and terms are visible, the note is strategic validation rather than unrestricted cash in this analysis.

Data access is an input, not yet a moat

Echo IQ's strongest potential advantage is the combination of clinical data, disease-specific models and integration inside hospital imaging workflows. Its exclusive Advara HeartCare licence offers access to as many as one million deidentified echocardiography studies. Mayo supplied an independent validation environment and a potential distribution channel. Mount Sinai and Beth Israel supply reference sites. Pro Medicus could add enterprise reach.

The pieces reinforce one another. More studies can improve model development and validation. More approved modules can raise revenue per hospital through the same integration. More hospital use can create implementation knowledge and economic evidence that lowers friction for later customers. This is the shape of a credible platform loop.

It has not yet produced a financial moat. FY2026 customer receipts were zero, reimbursement is unsettled, and the FDA decision shows that a rich dataset does not guarantee the required regulatory comparison. The company also terminated an older NEDA agreement in February 2025 and wrote down the related contract asset, a reminder that data rights are contractual assets rather than permanent property (Echo IQ 2025).

The moat classification is therefore mixed. Data access and workflow integration are stable assets. Regulatory evidence is eroding for HF but intact for AS. Distribution relationships are promising yet conditional. A widening label would require recurring commercial revenue, renewal or expansion inside existing systems, and a repeatable regulatory route for additional indications. None is visible in the filed numbers yet.

A capital raise at A$1.45 now frames every decision

The placement is central to the capital-allocation record because it happened ten weeks before the shares closed at A$0.64. The raise was well timed from the company's perspective: it transferred regulatory and commercial risk to new equity capital at more than twice the current price. Existing holders accepted 75.862 million new shares, roughly 11.5% of the pre-placement base, in exchange for a long runway (Echo IQ 2026c).

Management now has latitude to choose among an HF resubmission, another regulatory route, AS commercialization, new disease modules and strategic deals. Flexibility is valuable only if priorities narrow after the FDA feedback. Funding every branch would raise fixed costs before any branch proves product-market economics.

The incentive structure deserves scrutiny alongside the cash. FY2026 share-based payments equalled A$6.189 million against A$92,000 of revenue. After year end, the board approved an A$200,000 bonus for executive chair Andrew Grover and a US$200,000 bonus for chief executive Dustin Haines in recognition of corporate activity including the placement. The annual report also listed 89.525 million options and performance rights at its publication date, before another two million director options were proposed in September (Echo IQ 2026b).

Some option exercise prices now sit below the market price and can bring in cash; others sit above it. The full overhang could lift the share count toward 830 million if milestones are met and securities convert. Scenario values below therefore use 800 million to 830 million shares rather than treating 740.725 million as a permanent denominator.

What 64 cents still assumes

A revenue multiple on FY2026 is useless: A$474 million of equity value divided by A$0.092 million of revenue would describe expectation, not economics. The fit-for-business method is a risk-adjusted sum of parts. It values post-raise cash, the cleared AS franchise, the unapproved HF option and other early modules separately, then discounts FY2031 franchise values back five years at 15%.

At the close, ordinary-equity value was A$474.1 million. Subtracting A$105.4 million of stated cash leaves about A$368.7 million of enterprise value. The base construction assumes A$65 million of residual cash after commercialization spending, A$70 million of FY2031 AS revenue valued at five times revenue, A$25 million for other indications, and A$250 million of potential FY2031 HF revenue at five times revenue if the product clears and commercializes. The five-year discount factor is 2.01.

On those assumptions, AS contributes A$174 million of present value. A fully successful HF branch contributes A$621 million before probability weighting. Using 800 million diluted shares, A$0.64 implies an HF regulatory-and-commercial success probability of about 40% after the cash, AS and other-module values are counted.

That reverse valuation is sensitive to AS. If FY2031 AS revenue is only A$40 million at four times revenue, the implied HF probability rises to about 55%. If AS reaches A$100 million at five times, it falls to about 28%. The current price is not treating the FDA decision as terminal. It is treating remediation as uncertain and making the cleared product carry more of the load.

FY2031 AS revenue assumption	HF probability 25%	HF probability 40%	HF probability 55%
A$40m	A$0.43	A$0.55	A$0.66
A$70m	A$0.52	A$0.64	A$0.76
A$100m	A$0.62	A$0.73	A$0.85

Sensitivity uses five times revenue for both modules, A$65 million residual cash, A$25 million for other modules, a 15% discount rate and 800 million diluted shares. It is an author model, not company guidance.

Four ways the timetable can resolve

The severe-downside case values residual cash at A$45 million after four years of spending, gives AS only A$10 million of FY2031 revenue at 2.5 times, assigns nothing to HF and adds A$5 million for other intellectual property. With 820 million diluted shares, the point estimate is A$0.08 and the range is A$0.05 to A$0.12. This case corresponds to an HF route that does not recover and an AS product that never progresses beyond limited deployments.

The bear case gives HF a 10% chance of commercial success, A$120 million of FY2031 revenue if successful and a four-times multiple. AS reaches A$35 million at four times, cash declines to A$55 million and other modules receive A$15 million. The point estimate is A$0.20, within a A$0.14 to A$0.27 range.

The base case uses the 40% HF probability inferred above, A$250 million of HF revenue if successful and five times revenue. AS reaches A$70 million at the same multiple. Residual cash is A$65 million, other modules receive A$25 million and the denominator is 800 million shares. The point estimate is A$0.64, with a A$0.52 to A$0.78 range. That coincidence with the closing price is a model output, not a bracket chosen around the tape.

The bull case assumes a curable FDA deficiency, broad HF authorization, successful distribution and reimbursement. HF reaches A$500 million of FY2031 revenue, AS A$120 million, and both receive six-times multiples. A 70% HF probability, A$70 million residual cash, A$50 million for the wider pipeline and 830 million diluted shares produce A$1.83, inside a A$1.45 to A$2.15 range.

The width is unavoidable. Moving one regulatory probability by 15 percentage points changes model value by about A$0.12 per diluted share. Changing AS FY2031 revenue by A$30 million changes it by roughly A$0.09. The unpublished FDA deficiencies and unreported contract economics dominate precision.

The anti-thesis is already in the accounts

The constructive reading says Wednesday's fall was too blunt. EchoSolv AS remains cleared, clinical use is rising, leading hospitals have deployed it, Mayo and Pro Medicus offer distribution routes, and A$105.4 million gives management time to repair HF without emergency financing. A future FDA path that uses the existing 17,000-patient dataset could restore much of the lost option value.

The anti-thesis does not need a hostile forecast. It sits in FY2026: A$92,000 of revenue, no customer cash receipts, A$10.6 million of operating cash use and A$6.2 million of share-based payments. The company scaled sales and implementation ahead of commercial proof. The FDA then rejected the equivalence case for the larger unapproved module. If AS cannot produce recurring cash while HF is remediated, the placement funds activity rather than compounding.

There is another asymmetry. The company has published strong Mayo performance statistics and broad pipeline counts, but not customer pricing, annual contract values, retention, paid scan volumes or gross margins. Three proposals covering 300 hospitals sound large; the annual report says they were not committed revenue. Until receipts arrive, the difference between evaluation and production remains the most important commercial fact.

For that reason, the 50% fall looks broadly justified rather than clearly excessive. The pre-event valuation treated a favorable HF route as near enough to fund a launch organization. The regulator disproved that timetable. The post-event valuation still preserves substantial HF option value and grants AS a meaningful future franchise despite negligible reported revenue.

Three disclosures now carry the story

The first is the FDA remediation path. A direct 510(k) resubmission using the existing study would preserve the shorter branch. A requirement for a new prospective study, a changed indication or a De Novo process would push the model toward the bear range. The decisive disclosure is not management's confidence; it is the work package agreed with the agency.

The second is paid AS conversion. Quarterly customer receipts below A$1 million by the June 2027 quarter would sit awkwardly beside a 70-plus-institution funnel. Receipts above that level, accompanied by repeat use and named production deployments, would give the standalone AS valuation an observable base.

The third is spending discipline. Two consecutive quarters above A$7.5 million of operating cash use would annualize beyond A$30 million and compress the runway toward 3.5 years. The same reports will show whether implementation spending is followed by receipts or merely by a larger pipeline.

Pro Medicus is a fourth cross-check rather than a substitute for those facts. An unconditional distribution agreement and funded initial note would validate commercial integration. A prolonged conditional state would leave investors with an announced relationship but no disclosed unit economics.

Source notes: confidence and missing evidence

Verification is partial. The triggering release, five annual reports, capital-raising documents, quotation notices, FDA process guidance, independent media index, macro source and peer filing were fetched and read. The point-in-time Finance API resolved EIQ to ECHOIQ LIMITED, supplied filings and historical prices through 8 September, and showed no corporate-action event explaining Wednesday's move. Its daily price series had not yet ingested the 9 September close, so the A$0.64 close and 50.0% move were reconciled to the completed TradingView session scan. Shares on issue came from the ASX quotation notice rather than TradingView's stale market-cap field.

The missing items are material. Echo IQ has not published the FDA response letter, exact predicate comparison, estimated remediation cost, revised filing date, customer pricing, paid annual contract values or gross-margin data. Pro Medicus note and distribution economics remain incomplete. Scenario values are author estimates built to expose those dependencies, not forecasts supplied by the company.

The market now prices Echo IQ as a funded, FDA-cleared AS platform plus a damaged but live HF option. What changes that description is concrete: the FDA work package, customer cash receipts and the rate at which A$105.4 million becomes regulatory and commercial evidence.

References

• (ASX 2026a) ASX company page for ECHOIQ LIMITED (EIQ), 9 September 2026.
• (Echo IQ 2026a) ECHOIQ LIMITED, EchoSolv HF FDA Application Update, 8 September 2026.
• (TradingView 2026) TradingView, ASX:EIQ completed-session market snapshot, 9 September 2026.
• (Google News 2026) Google News RSS index of independent reports on the EIQ fall and FDA setback, 9 September 2026.
• (Echo IQ 2026b) ECHOIQ LIMITED, FY2026 Annual Report, 28 August 2026.
• (Echo IQ 2025) Echo IQ Limited, FY2025 Annual Report, 25 September 2025.
• (Echo IQ 2024) Echo IQ Limited, FY2024 Annual Report, 30 September 2024.
• (Echo IQ 2023) Echo IQ Limited, FY2023 Annual Report, 27 September 2023.
• (Echo IQ 2022) Echo IQ Limited, FY2022 Annual Report, 30 September 2022.
• (Echo IQ 2026c) ECHOIQ LIMITED, A$110m institutional placement, 1 July 2026.
• (Echo IQ 2026d) ECHOIQ LIMITED, Convertible note executed with Pro Medicus, 17 August 2026.
• (Echo IQ 2026e) ECHOIQ LIMITED, Application for quotation of securities, 21 August 2026.
• (FDA 2024) US Food and Drug Administration, Premarket Notification 510(k), 22 August 2024.
• (CDC 2026) US Centers for Disease Control and Prevention, About Heart Failure, accessed 9 September 2026.
• (HeartSciences 2026) HeartSciences Inc., FY2026 Form 10-K, 23 July 2026.